RedShiftBio Bio-Expo Live November 2025: Data, Quality, & Analytics

When a manufacturing change led to reduced potency in a peptide-based active pharmaceutical ingredient (API), Axxium Life, Inc. faced a challenge that conventional analytical methods couldn’t detect. By leveraging AuroraTX and RedShift Bio’s MMS technology, the company was able to uncover critical differences in higher-order structures—specifically, peptide aggregation—that were directly linked to the altered process.

This insight not only clarified the root cause of the potency issue but also demonstrated the value of MMS for both quality control and process development. For teams working with complex biologics, explore how advanced structural analysis can reveal what traditional assays miss.